Dan Douer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan Douer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alexandra M. Levine
Division of Hematology, Department of Medicine, and
2 shared publicationsKristy Watkins
Division of Hematology, Department of Medicine, and
2 shared publicationsAdam R. Craig
ILEX Oncology Inc., San Antonio, TX, USA
1 shared publicationAntonia P. Periclou
Department of Pediatrics, Division of Hematology/Oncology, Childrens Hospital Los Angeles, University of Southern California Keck Medical School and Norris Comprehensive Cancer Center, Los Angeles
1 shared publicationHenry Yampolsky
Division of Hematology, Department of Medicine, and
1 shared publicationJane M. Weiss
ILEX Oncology Inc., San Antonio, TX, USA
1 shared publication
Latest Publications
- 1 December 2008
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 21 (4) , 647-658
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
- 1 December 2008
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 21 (4) , 647-658
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
- Open Access
- 28 November 2006
- Published by American Society of Hematology in Blood
- Vol. 109 (7) , 2744-2750
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia
In contrast to that in children, pharmacokinetic, pharmacodynamic, and safety information on pegaspargase in adults is very limited. We administered a single intravenous dose of pegaspargase (2000 IU/m2) as part of a standard frontline induction regimen to 25 adults with newly diagnosed acute lymphoblastic leukemia (ALL), and obtained serum samples on several time points. The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2. After the single dose, asparagine deamination was complete in all patients after 2 hours, and in 100%, 81%, and 44% on days 14, 21, and 28, respectively. A pharmocodynamic correlation model showed minimal enzymatic activity of 0.2 IU/mL for optimal asparagine depletion. The kinetic posthoc analyses demonstrated enzymatic activity for 3 weeks or more. One patient developed neutralizing antiasparaginase antibodies on day 22 after administration. Pegaspargase was well tolerated, with few grade 3/4 side effects. No allergic reactions or pancreatitis were observed. In adults aged 55 years or younger, pegaspargase produces a long duration of asparagine depletion and can be given intravenously, with a safety profile that is similar to equivalent multiple doses of intramuscular Escherichia coli asparaginase.
- 28 November 2006
- Published by American Society of Hematology in Blood
- Vol. 109 (7) , 2744-2750
Open AccessPharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia
In contrast to that in children, pharmacokinetic, pharmacodynamic, and safety information on pegaspargase in adults is very limited. We administered a single intravenous dose of pegaspargase (2000 IU/m2) as part of a standard frontline induction regimen to 25 adults with newly diagnosed acute lymphoblastic leukemia (ALL), and obtained serum samples on several time points. The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2. After the single dose, asparagine deamination was complete in all patients after 2 hours, and in 100%, 81%, and 44% on days 14, 21, and 28, respectively. A pharmocodynamic correlation model showed minimal enzymatic activity of 0.2 IU/mL for optimal asparagine depletion. The kinetic posthoc analyses demonstrated enzymatic activity for 3 weeks or more. One patient developed neutralizing antiasparaginase antibodies on day 22 after administration. Pegaspargase was well tolerated, with few grade 3/4 side effects. No allergic reactions or pancreatitis were observed. In adults aged 55 years or younger, pegaspargase produces a long duration of asparagine depletion and can be given intravenously, with a safety profile that is similar to equivalent multiple doses of intramuscular Escherichia coli asparaginase.
- 1 April 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (10) , 2396-2410
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces complete remission in 87% of patients and molecular remission in 83% of patients. Two-year overall and relapse-free survival estimates are 63% and 49%, respectively. Treatment with arsenic trioxide may be associated with the APL differentiation syndrome, leukocytosis, and electrocardiographic abnormalities. The expanded use of arsenic trioxide in APL for postremission therapy, in conjunction with transplantation, and in patients with newly diagnosed APL is under investigation. The multiple mechanisms of action of arsenic trioxide suggest that it may have antitumor activity in malignancies other than APL and that it may be used in combination with other agents to expand its potential use. This article reviews the clinical use of arsenic trioxide to date and discusses new therapeutic strategies evolving from its diverse biologic activities.
- 1 April 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (10) , 2396-2410
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces complete remission in 87% of patients and molecular remission in 83% of patients. Two-year overall and relapse-free survival estimates are 63% and 49%, respectively. Treatment with arsenic trioxide may be associated with the APL differentiation syndrome, leukocytosis, and electrocardiographic abnormalities. The expanded use of arsenic trioxide in APL for postremission therapy, in conjunction with transplantation, and in patients with newly diagnosed APL is under investigation. The multiple mechanisms of action of arsenic trioxide suggest that it may have antitumor activity in malignancies other than APL and that it may be used in combination with other agents to expand its potential use. This article reviews the clinical use of arsenic trioxide to date and discusses new therapeutic strategies evolving from its diverse biologic activities.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (12) , 2135-2136
Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia
Refractory AML patients have a very poor prognosis. Therefore, rationally designed new therapies, including clofarabine, are being investigated as potential treatments for this patient population. This is a case report of a patient with primary refractory AML who was treated with clofarabine and achieved a complete response.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (12) , 2135-2136
Induction of Complete Remission Using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia
Refractory AML patients have a very poor prognosis. Therefore, rationally designed new therapies, including clofarabine, are being investigated as potential treatments for this patient population. This is a case report of a patient with primary refractory AML who was treated with clofarabine and achieved a complete response.